Every article, report, and earnings note where TMO appears.
Thermo Fisher Scientific Inc. (TMO) gained after a detailed Q3 2026 earnings beat, with stronger EPS, revenue, and margin expansion. The analysis goes beyond the headline, unpacking segment trends, guidance raises, and the tariff refund boost behind the move.
Davion Healthcare Plc is set to list on Nasdaq on 2026-10-22, with a price range not disclosed and a market cap of $252,750,000. The company is coming public as a direct listing, so there is no traditional underwritten IPO bookbuild or IPO proceeds. The bull case is a pre-revenue medtech story with multiple registered products and a consumer OTC model. The bear case is that the stock starts trading without the cushion of an IPO raise, while cash remains extremely thin and execution risk is high.
Thermo Fisher is delivering strong revenue, margin, and EPS growth across its core life sciences businesses, but the stock already prices in much of the recovery. The report lands on a Hold as valuation and leverage limit upside from here.
Thermo Fisher Scientific Inc. (TMO) gains 1.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
A seven-stock countdown explores quality across life sciences tools, from challenged platforms to profitable analytical, diagnostic, and research franchises.
Thermo Fisher Scientific Inc. (TMO) rises after a broad Q2 beat, margin expansion, and a full-year guidance raise. This deep-dive examines the company’s share-gain narrative, end-market strength, five-quarter EPS beat streak, and what the stronger organic growth outlook could mean for the stock.
Thermo Fisher Scientific Inc. (TMO) climbs 10.1% after reporting earnings beats, lifting investor sentiment as the company tops expectations and signals stronger-than-expected performance.
Thermo Fisher Scientific Inc. (TMO) rises sharply after a strong second-quarter earnings report topped Wall Street expectations on both profit and revenue. The healthcare tools giant also posted solid organic growth, signaling firmer demand and prompting investors to reprice the stock higher.
A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.
Thermo Fisher Scientific Inc. (TMO) drops after reporting a Q1 2026 earnings beat on revenue and EPS. Investors are focusing instead on margin pressure, mixed segment performance, and whether guidance can justify the stock’s premium valuation.
Thermo Fisher Scientific Inc. (TMO) slips 2.0% after reporting earnings that met expectations, as investors react to the latest quarterly results.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate TMO ReportCancel anytime